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tus occurred at the time of presentation with AMI and at randomization Into VALIANT 
(median 4.6 days after presentation). Pts with a history of DM or insulin use prior to the 
qualifying MI were defined as previously known DM (n=3.421). Newly diagnosed DM 
(n=565) was defined as pts with DM. some of whom required diabetic therapy at random- 
ization; none had known DM at presentation. The primary outcome was 30-day mortality. 
Results: Compared with known DM, pts with new DM were younger and had less hyper- 
tension, dyslipidemia. or prior cardiovascular disease, but had similar LV ejection fraction 
and Killip class at presentation. As anticipated, known DM had a higher 30-day mortality 
than that for non-diabetics. However, the overall adjusted risk for death associated with 
new DM was more similar In magnitude to previous DM than that for non-diabetics. 
Conclusion : Previously known DM is associated with higher do-day mortality in high-nsk 
pts presenting with an AMI. Despite less cardiac co-morbidity, newly diagnosed DM has 
a similar prognosis to previously known DM. 
Mean age 
LV ejection fraction (available for 77% 
of patients) 
Killip class > I 
Hypertension 
Dyslipidemia 
Prior MI 
Prior heart failure 
Prior stroke 
30.day mortality 
Adjusted hazard ratio for 30-day 
mortality (95% Cl) 
Known DM New DM 
(n=3,421) (n=565) 
NC+ 
diabetics 
(n=10,795 
66.6 * 10.4 63.9* 11.8’ 
34.4 * 10.4 34.1 * 10.4 
76.5% 75.6% 
70.3% 54.5%’ 
42.4% 21.7%’ 
34.7% 22.1%’ 
22.5% 9.7%’ 
9.4% 3.4%* 
5.0% 5.2% 
1.22 (1.01, 1.47) 1.24 (0.65, 
1.80) 
64.4 * 
12.2 
34.9 * 
10.2 
70.4% 
50.3% 
26.3% 
26.1% 
12.7% 
5.2% 
3.7% 
1 .oo 
(Referent 
e) 
*New DM vs Known DM, p <O.OOl 
3:45 p.m. 
1066A-MP-206 Prognostic Value of C-Reactive Protein in Diabetic 
Patients With Unstable Angina 
Javier N. Guena. Juan J. Fuselli. Carlos P. Boissonnet. Enrique Fairman. Alfred0 
Piombo, Juan Gagliardi, DIC Group, Buenos Aires, Argentina 
Background: In diabetic (DBT) patients (p), atherosclerotic plaques contain more inflam- 
matory cells, suggesting higher plaque vulnerability. 
Purpose: To determine the prognostic value of HS C-reactive protein (CRP) in DBT p 
with unstable angina (UA), in order to predict in-hospital death and/or MI (D/Ml). 
Methods: Multicenter, prospective study. Of the 317 consecutive p herein included, 67 
were diabetic (21 .l%). CRP (positive value: higher tertile) and cTnT (positive value: 3 0.1 
@ml) were measured at admission >= 6 hours from qualifying episode. In-hospital D/MI 
rate was 7.6%. CRP values were higher in DBT p than in non-DBT p: 1.64 * 2.5 vs 1.23 
f 2.9 mg/dl: p=O.OOl, t test (prior log transformation). D/MI was higher in DBT p (14.9% 
vs 5.6%. p=O.OZ) and in p with CRP (+) (11.3% vs 5.7%, p=O.O4). In a logistic regression 
model including CRP and cTnT. cTnT (c) was predictive of D/Ml (OR 3.5, Cl 95% 1.5- 
6.2, p=O.O05), whereas CRP was not (~~0.3). In the subgroup of DBT p, the Incidence of 
D/Ml was 29.2% in p with CRP (+) vs 7.0% in those with CRP (-) (OR 5.5, Cl 95% 1.3- 
23.6, p=O.O4) (Figure). In the logistic regression analysis performed in DBT p, CRP (+) 
was an independent predictor of D/MI (OR 4.6, Cl 95% 1.03-20.4. p=O.O46), whereas 
cTnT (+) was not. 
Conclusion: CRP levels are higher in DBT p with unstable angina. This marker is a stron- 
ger predictor of D/Ml than cTnT(+) I” this subgroup of p. These data suggest that plaque 
inflammation plays a major role in the genesis and evolution of plaque instability in DBT p 
with unstable angina. 
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1071-106 The Effect of Combination Use of Ticlopidine and 
Aspirin on 30-Day Mortality in Patients With Acute 
Myocardial Infarction 
Hlrova Mizunq Hiroshi Sate, Kunihiro Kinjo, Dalsaku Nakatani, lssei Shiotani, Eiji 
Hishida. Atsushi Hiravama. Kazuhisa Kodama. Masatsuou Hori. Osaka Acute Coronarv 
I  1  
Insufficiency Study (OACIS) group, Osaka University, Osaka, Japan 
Background. Combination therapy with clopidogrel and aspirin is proved to be superior 
to aspirin alone in the prevention of major vascular ischemic events in patients with acute 
coronary syndrome without ST-segment elevation in the CURE trial. However, advan- 
tage of the combination use of thienopyridines in broad spectrum of acute myocardlal inf- 
arction (AMI) has not been thoroughly clarified. We evaluated the effect of combination 
use of ticlopidine on thirty-day mortality in patients of AMI including ST-elevation infarc- 
tion. Subjects and methods. Of consecutive 2723 patients with AMI who registered to 
Osaka Acute Coronary Insufficiency Study, 1709 patients receiving ticlopidine and/or 
aspirin were enrolled in this study. Patients receiving other antiplatelets were excluded. 
The patients were divided into two groups according to the antiplatelet therapy: group 
treated by aspirin alone (n=768) and group treated by combination use of aspirin and 
ticlopidine (n=941). We compared thirty-day clinical outcome and major adverse event 
between the two groups by unadjusted Kaplan-Meier method, chi-square analysis and 
multivariate logistic regression models. Results. Within thirty days of onset, combination 
therapy group showed significantly lower all-cause mortality (0.9% versus 5.9%, 
p<O.OOOl) than aspirin group. After adjustment by patient characteristics, coronary risk 
factors and therapies, combination therapy remained as an independent predictor of 
thirty-day mortality (Odds ratio 0.16, [95% Cl 0.0046.0.511. p=O.O023). Combination ther- 
apy also decreased a risk of a composite of cardiovascular death and Ml (Odds ratio 
0.45, [95% Cl 0.24-0.641, p=O.O13). Significant diflerences were not observed in major 
bleeding between the two groups. Conclusion.Though it is not in a randomized fashion, 
our data suggested that combination use of ticlopidine has more favorable effect on 
thirty-day prognosis than aspirin monotherapy when applied to a broad spectrum of 
patients with AMI. 
1071-107 Predictors and Long-Term Mortality of Atrioventricular 
Block After Acute Myocardial Infarction Treated With 
Thrombolysis 
Trip J. Meine, Sana M. Al-Khatib, John H. Alexander, Christopher C. Granger, Rakhi 
Kilaru. Kathryn Williams, E. Magnus Ohman, Eric J. Topol, Robert M. Califf, Duke Clmical 
Research Institute, Durham. NC 
Background: Since the advent of thrombolylic therapy, several studies have suggested 
that the rate of post-myocardial Infarction atrwentricular block (AVB) remains high and 
is associated with increased mortality. We sought to further delineate the predictors of 
AVB and the long-term mortality of patients developing AVB in the setting of ST-segment 
elevation myocardial infarction treated with thrombolytic therapy. 
Methods: We combined four studies of ST-segment elevation myocardial infarction 
(GUSTO-I, GUSTO-lib, GUSTO-III and ASSENT-II) into a large database (n=75.993). 
We identified independent predictors of second and third degree AVB and compared the 
6.month and l-year mortality rates of patients with AVB (5,251) with those of patients 
without AVB (70,742). 
Results: The incidence of AVB was 6.9%. Significant Independent predictors of AVB are 
summarized in the table. Adjusted mortality was significantly higher in patients with AVB 
than patients without AVB at 6 months (OR 1.6, 95% Cl 1.4-l .6) and at 12 months (OR 
1.3, 95% Cl 1.1-1.5). 
Conclusion: In the thrombolytic era, AVB is not only a common complication of ST-seg- 
ment elevation myocardial infarction, but portends higher mortality. Future studies should 
focus on determining therapies that are effective at reducmg the mortality rates of these 
patients. 
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Female Sex 
Older Age 
Unstable Angina 
Pulse<65 at Presentation 
Hypotension at Presentation 
Diabetes 
Hypertension 
Active Smoking 
Inferior MI 
Worse Killip Class 
Predictors of AVB 
Odds Ratio 96% Cl 
1.3 1.2-l .4 
1.2 1.2-1.3 
1.2 1.2-l .3 
0.6 0.6-0.6 
1.2 1.2-I .3 
1.2 1.1-1.3 
1.1 1.1-1.2 
1.2 1.1-1.3 
3.3 3.1-3.5 
1.3 1.2-l .4 
1071-108 Right Ventricular Behavior in Left Ventricular Infarction 
lhab S. Ramzy, Christine A. O’Sullivan, Andrew J. Coats, Derek G. Gibson, Michael Y. 
Henein. Central Middlesex Hospital, London, Umted Kingdom, Royal Brompton Hospital, 
London, United Klngdom 
Background: Patients with acute myocardial infarction (Ml) may develop tranwnt right- 
sided signs for which it may be difficult to give a physiological explanation. 
Aim: To assess right ventricular (RV) function I” patients with acute Ml at admission and 
follow up after thrombolysis. 
Methods: We studied RV function In 26 patients with acute MI and no clinical manifesta- 
tions of heart failure, 10 anterior Ml (age 65+12 years) and 16 inferior MI (age 54~10 
years). RV function was assessed from free wall excursion using echocardiography. Val- 
ues were compared with those from 21 age-matched controls. 
Results: Before thrombolysis, RV free wall amplitude was depressed 1.8kO.4 vs 
2.5~0.25 cm only in anterior MI, as was peak shortening rate 6.8+1.8 vs 10.0*2 cmfs and 
peak lengthening rate 6.3*2.7 vs 10.0+2.5 cm/s, compared with normal (pcO.01 all). 
After thrombolysis. these disturbances progressively Improved towards normality until 30 
days; RV amplitude 2.3*0.5 cm, peak shortening rate 8.6+ 2.2 cm/s and peak lengthen- 
mg rate 8.2* 3.8 cm/s, (all NS). These disturbances were not found with inferior MI. 
Conclusion: In acute anterior MI, even in the absence of left heart failure, there IS a sig- 
nificant disruption of right ventricular systolic and diastolic function. These abnormalities 
tend to normalize within 30 days of thrombolysis. Thus, they may contrIbute to the known 
hemodynamic disturbances seen with anterior Ml. 
1071-109 Diastolic Ventricular Electromechanical Response to 
Thrombolysis for Acute Myocardial Infarction 
lhab S. Ramzy, Mark C. Dancy. Derek G. Gibson, Andrew J. Coats, Michael Y. Hewn, 
Central Middlesex Hospital, London, United Kingdom. Royal Brompton Hospital, London, 
United Kingdom 
Background: Left ventrwlar response to acute myocardial infarction (Ml) differs accord- 
ing to its location, anterior and inferior. 
Aim: To study diastolic ventricular electromechanical behavior after thrombolysis for 
acute Ml in patients with anterior and Inferior Ml. 
Methods: We studied 21 patients with acute MI; 11 anterior (age 5228 years) and 10 
inferior (age 59216 years) at admisslon durmg thrombolysis and 30 days post recovery 
using ECG and echocardlography. Electromechanical segmental delay was taken from 
the end of the T wave to the onset of segmental long axis lengthening in early dlastole. 
ST and T wave duration were compared with corresponding segmental mechanical 
delay, anterior and posterior segments. 
Results: In patients with inferior Ml the delayed onset of the posterior long axis lengthen- 
ing was not different from normal 69128 vs 65-10 ms (NS) with respect to end election. 
This delay correlated closely with ST segment (r=-0.8. pcO.001) and T wave (r=0.9, 
pcO.001) duration. In contrast, with anterior InfarctIon the onset of anterior long axis 
lengthening was delayed by 20ms, 80124 vs SO+9 ms. pcO.001 compared to normal. 
This delay became only related to ST duration 30 days after Ml infarction (r=0.8, 
p<O.OOl) but not with the T wave. 
Conclusion: Patients with Inferior Ml preserve their diastllc electromechanical relation- 
ship within days after thrombolysis, however with anterior infarctIon this relationship is 
lost suggesting significant ventricular remodeling. 
1071-110 Delays in Revascularization Are Associated With an 
increased Risk of Stroke in Patients With Myocardial 
Infarction 
Eric Van De Graaff, Enc A. Shry, Paul D. Frederick, Nathan Every, Martha Blaney, Morris 
Cheeks, Steven R. Stelnhubl. Wright Patterson Medical Center, Dayton, OH, Ovation 
Research Group, HIghland Park, IL 
Background: Nonhemorrhagic cerebrovascular accident (NHCVA) is a rare but devastat- 
mg complication of myocardial infarctlon (Ml). The effect of timing of revascularization on 
risk Of NHCVA has not been assessed. Methods: We utilized the National Registry of 
Myocardial Infarction 3 and 4 databases to identlfy 45,997 patients who underwent 
thrombolytic therapy and 47,876 patients who were treated with primary percutaneous 
trenSiuminsl coronary angioplasty (PTCA) for Ml. NHCVA occurred in 248 (0.54%) and 
150 (0.31%) patients in the two groups, respectively. We stratIfled these based on time 
from presentation to Initial therapy. Results: A statistically significant linear relationship 
between time to revascularlzation and risk of in-hospital NHCVA was seen on univariate 
analysis (Tables). A multivariate model incorporating 39 other variables showed throm- 
bolyiic therapy within 15 minutes and primary angioplasty within 90 minutes of arrival to 
be associated with a lower risk of NHCVA (OR 0.584 [95% Cl 0.362.0.9421, and OR 
0.363 [95% Cl 0.147.0.8961, respectively). Conclusion: Risk of in-hospital NHCVA with 
Ml is directly related to time to revascularization with both thrombolytic and PTCA thera- 
pies. Early revascularization IS independently predictive of a low risk of NHCVA. 
1071-111 Regional Variations in Treatments and Outcomes of 
Reinfarction in the HERO-2 Trial 
John J. Edmond, John K. French. Philip E. Aylward, Cheuk-Kit Wang. Ralph A. Stewart, 
Barbara F. Williams, Carmine De Pasquale. Rachel O’Connell, John Simes. Harvey D. 
White, For the HERO-2 Investigators, Green Lane Hospital, Auckland, New Zealand, 
NHMRC Clinical Trials Center, University of Sydney, Sydney, Australia 
Background and Methods: Compared to patients without reinfarction @MI), patients 
with reMl during the initial hospitalization for ST elevation Ml treated with fibrinolytic ther- 
spy have poorer outcomes. ReadministratIon of fibrinolytic therapy and/or revasculanza- 
tlon procedures following reMl have been associated with better outcomes. We 
examined clinical, electrocardiographic and cardiac marker profile data SuppIled to the 
ClInical Endpoints Committee (CEC) for reMl to determine associations between treat- 
ment of reMl and mortality. 
Results: Of 17073 patients enrolled in the HERO-2 trial, 552 cases were CEC adjudi- 
cated as having had reMI. Amongst these, readmmistration of thrombolytic therapy alone 
occurred in 11.4%, revascularlzatlon was performed within 12 hours of reMl I” 8.7% and 
conservative therapy occurred in 79.9%; in Western countries (n=l12), these treatments 
were 32.1%. 18.8% and 49.1% respectively (p<O.OOl). After reMl (compared to patients 
without reMI), mortality wlthln 30 days of randomization was increased (24% vs IO%, 
pcO.001 by Cox Model) and varied across geographic regions (highest South America 
(29%), lowest Western countries (15%), p=O.O8). Following reMI, mortality was 15% in 
patients readministered thrombolytic therapy and/or had revascularization at cl2 hours 
of reMl and 27% when no treatment was given (HR 0.53(95%Cl 0.32.0.88), p=O.Ol). 
Treatment was stall associated with a lower risk when deaths within 12 hours of reMl 
were excluded (HR 0.51 (95% Cl 0.28.0.90), p=O.O17), but the hazard ratio was 0 65 
(95%CI 0.36-1.16, ~~0.143) when adjusted for other significant predictors of death fol- 
lowing reMI- namely age, time to reMl and Killlp class at entry. 
Conclusion: Remfarction. which varied according to geographic region, IS associated 
with a significantly higher mortality wthin 30 days of randomization. However, thromboly- 
sis or revascularization ~12 hours in patients with reMl was associated with lower mortal- 
ity. 
1071-112 Possible Beneficial Effects of Adenosine as Adjuvant 
Therapy to Thrombolytic Treatment in Patients With en 
Acute Anterior Myocardial Infarction and Depressed 
Left Ventricular Function 
Mww?l L. Qumtane Paul Hjemdahl. Alf Sollevi, Thomas Kahan. Nina Rehnqvist. Magnus 
Edner, Eva Swahn, Karollnska Institutet, Stockholm, Sweden 
Backgrounct Ammal expenmental results suggest that adenosine may prevent reperfu- 
sion injury by anti-iflammatory effects.The AmACC (Attenuation by Adenosine of Car- 
diac Complications) study was a randomized double blind placebo-controlled trial of a 
low anti-inflammatory dose of adenosine given by a 6 h intravenous Infusion in 608 
patients treated with thrombolysls for an acute myocardial infarction (Ml). Methods: A 
post-hoc analysis was performed I” patients with anterior Ml and depressed left ventrw- 
lar function, as assessed by a wall motion score index greater than 1.5 on 2-D echocar- 
diography on 4 (range 2-10) days after hospital admisslon. Results: In the 292 patients 
with anterior Ml one-year all cause mortality was 12 (8.4%) in the adenosine group ver- 
sus 23 (15.3%) ln the placebo group, OR 0.5, 95% Cl 0.2-1.1. P=O.O7. Cardiovascular 
mortality was 12 (8.4%) versus 22 (14.6%). OR 0.5, 95% Cl 0.3-l .l, P=O.O8. The rates of 
non-fatal MI and combined cardiovascular events were similar in both groups. In 181 
patients with anterior Ml and depressed left ventricular systolic function, one-year all 
cause mortality was 2 (2.0%) in the adenosine group versus 10 (12.1%) I” the placebo 
group, OR 0.16, 95% Cl 0.03-0.7. P=O.O07 Cardiovascular mortality was 2 (2.0%) ver- 
sus 9 (10.8%), OR 0.19, 95% Cl 0.03-0.8, P=O.OlO. Rates of non-fatal Ml and combined 
cardiovascular events were similar in both groups. Conclusions: A low anti-inflamma- 
tory dose of adenosine gfven by intravenous infusion may have positive effects on clinical 
outcome in patients with an anterior Ml and depressed left ventricular function treated 
with throbolysls. Larger trials are warranted to confirm these findings. 
